| Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript |
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2025 Earnings Call May 12, 2025 4:30 PM ET Company Participants Brian Ritchie - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Yair Lotan - Chief, Urology and Oncology Conference Call Participants Uy Ear - Mizuho Securities Matt Barcus - Jefferies Operator Good afternoon. Welcome to the Relmada Therapeutics First Quarter 2025 Earnings Call. |
seekingalpha.com |
2025-05-13 02:02:34 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) |
globenewswire.com |
2025-05-12 20:01:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 |
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. |
globenewswire.com |
2025-05-08 11:30:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 |
90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation* |
globenewswire.com |
2025-04-28 17:38:00 |
Czytaj oryginał (ang.) |
| UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 |
globenewswire.com |
2025-04-27 13:00:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data |
April 28 th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced it will host a virtual key opinion leader (KOL) event on Monday, April 28, 2025 at 4:30 PM ET. |
globenewswire.com |
2025-04-24 12:00:00 |
Czytaj oryginał (ang.) |
| UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. |
globenewswire.com |
2025-04-14 12:41:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. |
globenewswire.com |
2025-04-14 11:30:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript |
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Uy Ear - Mizuho Securities Andrew Tsai - Jefferies Operator Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-03-27 22:07:05 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update |
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-03-27 18:05:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 |
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. |
globenewswire.com |
2025-03-26 11:00:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. |
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) |
globenewswire.com |
2025-03-25 09:30:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB |
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB |
globenewswire.com |
2025-02-06 09:30:00 |
Czytaj oryginał (ang.) |
| Relmada discontinues late-stage trials for depression drug, explores sale |
Relmada Therapeutics said on Monday it would discontinue the two late-stage studies planned for the development of its depression drug and explore strategic alternatives including a sale. |
reuters.com |
2024-12-09 10:11:35 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 |
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value |
globenewswire.com |
2024-12-09 09:30:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why |
On Wednesday, Relmada Therapeutics, Inc. RLMD announced a preplanned interim analysis of the Reliance II Phase 3 study. |
benzinga.com |
2024-12-04 16:02:24 |
Czytaj oryginał (ang.) |
| Relmada's depression drug unlikely to meet main trial goal, analysis shows |
Relmada Therapeutics' depression treatment is "unlikely" to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee's analysis. |
reuters.com |
2024-12-04 10:00:56 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance |
The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024 CORAL GABLES, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the pre-planned interim analysis of Reliance II, conducted by the Independent Data Monitoring Committee (DMC), indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance. |
globenewswire.com |
2024-12-04 09:30:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm |
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. |
globenewswire.com |
2024-11-21 15:34:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease |
REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initiation of dosing in a Phase 1 SAD study of REL-P11, an investigational agent for metabolic disease. |
globenewswire.com |
2024-11-14 09:30:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript |
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2024 Earnings Call November 7, 2024 4:30 PM ET Company Participants Tim McCarthy - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Operator Hello and welcome to the Relmada Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the location website. |
seekingalpha.com |
2024-11-10 11:39:57 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update |
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla. , Nov. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2024. |
prnewswire.com |
2024-11-07 18:32:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update |
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company |
globenewswire.com |
2024-11-07 18:10:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 |
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-04 18:30:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm |
NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD) breached their fiduciary duties to shareholders. |
prnewswire.com |
2024-09-17 01:36:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm |
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. |
globenewswire.com |
2024-09-05 13:29:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-08-12 14:36:45 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript |
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Tim McCarthy - Investor Relations, LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Rudy Li - Leerink Partners Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Operator Good afternoon. Welcome to the Relmada Therapeutics Inc.'s Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-09 10:25:09 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update |
Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for metabolic disorders by YE 2024 Cash position of $70.4 million provides runway through key milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla. , Aug. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the second quarter ended June 30, 2024. |
prnewswire.com |
2024-08-07 20:05:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 |
CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. |
globenewswire.com |
2024-08-05 11:30:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue |
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-07-30 13:45:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue |
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-07-29 23:15:00 |
Czytaj oryginał (ang.) |
| Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue |
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-07-26 20:15:00 |
Czytaj oryginał (ang.) |